Syndax Pharmaceuticals Inc (SNDX) Form 8-K — Apr 30, 2026
Syndax Pharmaceuticals reported total revenue of $64.9 million for the first quarter of 2026, a 224% increase year-over-year, driven by the strong commercial performance of Revuforj and Niktimvo. Revuforj net revenue reached $48.9 million, up 144% from the prior year, while Niktimvo collaboration revenue contributed $15.9 million based on $55.1 million in total net product revenue reported by partner Incyte. The company narrowed its net loss to $42.7 million, or $0.48 per share, compared to a loss of $84.8 million in the same period last year.
Key figures
- Eps
- -0.48
- Revenue
- 64.9 million
- Guidance
- Total research and development plus selling, general and administrative expenses to be approximately $400 million
- Net Income
- -42.7 million
- Revenue Yoy
- 224%
- Cash Position
- 352.1 million
- Shares Outstanding
- 88.8 million
Price after filing
Close on the filing date to close N calendar days later (from $21.43). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.